Zenas Biopharma Inc

Important metrics include cash and short-term investments, total assets, current assets, total liabilities, current liabilities, long-term debt, shareholders' equity, retained earnings, inventory, receivables, working capital, current ratio, quick ratio, debt-to-equity ratio, and return on equity. Investors usually review these together rather than relying on one number.

Assets are resources the company owns or controls, such as cash, receivables, inventory, investments, and property. Liabilities are obligations the company owes, such as accounts payable, debt, leases, and taxes. Shareholders' equity is the residual value after liabilities are subtracted from assets.

Current assets and current liabilities are generally expected to be converted, used, paid, or settled within one year or one operating cycle. Non-current assets and non-current liabilities are longer-term items, such as property, long-term investments, deferred tax assets, long-term debt, and lease obligations.

In its most recent quarterly, Zenas Biopharma Inc had 500.22M in cash and cash equivalents.

Zenas Biopharma Inc reported 141.50M in total liabilities as of the latest reported quarter, including 62.65M in current liabilities and 78.85M in non-current liabilities.

As of the latest reported quarter, Zenas Biopharma Inc's total assets were 383.64M, consisting of 351.17M in current assets and 32.47M in non-current assets.

Zenas Biopharma Inc reported 242.14M in total shareholders' equity as of the latest reported quarter.